Stock listing

Lang & Schwarz:A40YSR BioXcel Therapeutics, Inc. Aktie

German listing (Lang & Schwarz) of BioXcel Therapeutics, Inc. · home listing NASDAQ:BTAI

Follow BioXcel Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BTAI

$0.048 USD -0.002 (-3.3%)

Close on Oct 8, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BTAI · Data provided by Twelve Data

Since Jul 1, 2026 -96.5% · daily closes, Jul 1, 2026 – Oct 8, 2026, adjusted for splits
Day range
$0.040 – $0.055 USDOct 8, 2026
Volume
70,578 sharesOct 8, 2026
BioXcel Therapeutics, Inc. logo
Ticker
Lang & Schwarz:A40YSR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Bioxcel Therapeutics (NASDAQ:BTAI) Q3 2024 Earnings Call

    Thu, Nov 14, 2024 · 8:00 AM ET

    Watch Transcript

  • Bioxcel Therapeutics (NASDAQ:BTAI) Q2 2024 Earnings Call

    Tue, Aug 06, 2024 · 8:00 AM ET

    Watch Transcript

  • Bioxcel Therapeutics (NASDAQ:BTAI) Q1 2024 Earnings Call

    Thu, May 09, 2024 · 8:00 AM ET

    Watch Transcript

Latest news

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

May 28, 2026

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Apr 17, 2026

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

Apr 8, 2026

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Apr 1, 2026

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting

Mar 30, 2026

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Mar 11, 2026

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Mar 10, 2026

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Mar 5, 2026

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia

Feb 19, 2026

All BioXcel Therapeutics, Inc. news

Decks

BioXcel Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 174 in all · newest May 28, 2026 · oldest 2019
Calls
14 calls with a replay · 14 with a transcript · latest Nov 14, 2024
Decks
21 decks · latest November 2025

Where BioXcel Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BTAI · Home listingNASDAQUnited StatesUSD
BOATS:BTAIBOATSUnited StatesUSD
LS Exchange:A40YSRLS ExchangeGermanyEUR
gettex:BX20gettexGermanyEUR
Lang & Schwarz:A40YSR · This pageLang & SchwarzGermanyEUR
Tradegate:BX20TradegateGermanyEUR
Dusseldorf:BX20DusseldorfGermanyEUR
Frankfurt:BX20FrankfurtGermanyEUR
Hamburg:BX20HamburgGermanyEUR
Munich:BX20MunichGermanyEUR
Stuttgart:BX20StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about BioXcel Therapeutics, Inc.